Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What is the current market size of the metastatic lung adenocarcinoma treatment industry, and what growth rate is it expected to achieve?
The metastatic lung adenocarcinoma treatment market size has grown rapidly in recent years. It will grow from $4.13 billion in 2024 to $4.55 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to the increasing incidence of lung cancer, the rising demand for targeted therapies, the rise in the adoption of immunotherapy, the growing investments in oncology research, and the increasing awareness about early detection and diagnosis.
The metastatic lung adenocarcinoma treatment market size is expected to see strong growth in the next few years. It will grow to $6.64 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to the rising prevalence of smoking and environmental factors, the increasing approval of novel drug therapies, the growing healthcare infrastructure in emerging markets, the rise in personalized medicine approaches, and the increasing collaborations between pharmaceutical companies and research institutions. Major trends in the forecast period include advancement in liquid biopsy technologies, advanced combination therapies for better outcomes, innovations in targeted drug delivery systems, advancement in AI-driven diagnostics for precision treatment, and advanced immuno-oncology treatments.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24320&type=smp
What are the major drivers contributing to the growth of the metastatic lung adenocarcinoma treatment market?
The increasing adoption of targeted therapy is expected to propel the growth of the metastatic lung adenocarcinoma treatment market going forward. Targeted therapy is a cancer treatment that uses drugs to precisely block cancer growth by targeting specific genes or proteins that drive tumor development and spread. Targeted therapy is gaining traction as it precisely addresses specific genetic mutations, resulting in more effective treatment outcomes and reduced side effects compared to conventional methods. Targeted therapy treats metastatic lung adenocarcinoma by blocking specific genetic mutations that drive cancer growth and spread. It offers a more precise approach with fewer side effects and can greatly enhance survival and quality of life in patients with actionable mutations. For instance, in July 2023, according to the American Society of Gene and Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, there were 247 gene therapies in Phase II at the end of the first quarter of 2023, increasing by 5% to 260 by the end of the second quarter. Therefore, the increasing adoption of targeted therapy is driving the growth of the metastatic lung adenocarcinoma treatment market.
What are the major market segments driving the growth of the metastatic lung adenocarcinoma treatment industry?
The metastatic lung adenocarcinoma treatment market covered in this report is segmented –
1) By Treatment: Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy
2) By Route of Administration: Oral, Intravenous
3) By End-User: Hospitals, Cancer Research Centers, Specialty Clinics
Subsegments:
1) By Chemotherapy Drugs: Platinum-Based Chemotherapy, Non-Platinum Chemotherapy, Combination Therapy, Single-Agent Chemotherapy
2) By Targeted Therapy,: Epidermal Growth Factor Receptor Inhibitors, Anaplastic Lymphoma Kinase Inhibitors, C-Ros Oncogene 1 Receptor Tyrosine Kinase Inhibitors, V-Raf Murine Sarcoma Viral Oncogene Homolog B1 Inhibitors, Rearranged During Transfection Inhibitors, Mesenchymal-Epithelial Transition Factor Inhibitors, Neurotrophic Tropomyosin Receptor Kinase Inhibitors
3) By Immunotherapy: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors, Combination Immunotherapy, CAR-T Cell Therapy (Emerging)
4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Stereotactic Body Radiotherapy (SBRT), Intensity-Modulated Radiation Therapy (IMRT), Proton Therapy
View The Full Market Report:
What are the key trends shaping the metastatic lung adenocarcinoma treatment market in the forecast period?
Major companies operating in the metastatic lung adenocarcinoma treatment market are focused on developing advanced solutions such as chemotherapy-free treatment to enhance long-term survival rates by targeting specific genetic mutations and improving patient outcomes. Chemotherapy-free treatment refers to cancer therapies that utilize alternatives such as targeted therapy or immunotherapy, aiming to manage cancer effectively while reducing the severe side effects typically linked to traditional chemotherapy. For instance, in August 2024, Johnson & Johnson, a US-based healthcare company, announced that the U.S. Food and Drug Administration (FDA) had approved RYBREVANT (amivantamab-vmjw) in combination with LAZCLUZE (lazertinib) as a first-line, chemotherapy-free treatment for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR exon 19 deletions or exon 21 L858R substitution mutations. The approval was supported by results from the Phase 3 MARIPOSA study, which demonstrated superior progression-free survival compared to osimertinib.
Who are the key market players contributing to the growth of the metastatic lung adenocarcinoma treatment industry?
Major companies operating in the metastatic lung adenocarcinoma treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Exelixis, BeiGene Ltd., Novocure, Blueprint Medicines Corporation.
Which regions are leading the growth of the metastatic lung adenocarcinoma treatment market globally?
North America was the largest region in the metastatic lung adenocarcinoma treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metastatic lung adenocarcinoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Metastatic Lung Adenocarcinoma Treatment Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/customise?id=24320&type=smp
Need Customized Data On Metastatic Lung Adenocarcinoma Treatment Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24320&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
